Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, discusses new agents and novel trials in advanced urothelial carcinoma (UC), including the use of antibody-drug conjugates, FGFR inhibitors and the promise of combination therapies and biomarkers. This interview took place at the PROSCA/BLADDR 2021 congress.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.